Treats metastatic non-small cell lung cancer (NSCLC). ANDA 216342, held by Eugia Pharma. Erlotinib Hydrochloride.
As of Nov 22, 2026, ANDA 216342 (Erlotinib Hydrochloride), held by Eugia Pharma, was first approved by FDA on Jun 22, 2022, with 0 approved supplements and 0 published complete response letters.
Erlotinib tablets are a kinase inhibitor indicated for: The treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen. First-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer, in combination with gemcitabine.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 22, 2022 | Original application | Approved | None posted |
| Erlotinib HydrochlorideEQ 25MG BASE · tablet;oral | Erlotinib Hydrochloride | Discontinued |
| Erlotinib HydrochlorideEQ 100MG BASE · tablet;oral | Erlotinib Hydrochloride | Discontinued |
| Erlotinib HydrochlorideEQ 150MG BASE · tablet;oral | Erlotinib Hydrochloride | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters